Cingulate Inc. (CING): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Cingulate Inc. (CING), a biopharmaceutical company making waves in the treatment of ADHD and anxiety disorders? With a strategic focus on advancing its lead candidate, CTx-1301, and a recent $3 million grant to accelerate the development of CTx-2103 for anxiety, Cingulate is poised to address significant needs in the $18 billion U.S. ADHD and $5.5 billion U.S. anxiety markets. But how did they get here, who's steering the ship, and what makes their approach unique? Keep reading to discover the history, ownership, mission, and how Cingulate Inc. operates and generates revenue.

Cingulate Inc. (CING) History

Cingulate Inc.'s Founding Timeline

Year established

The company was established in 2011.

Original location

The company's original location was in Kansas City, MO.

Founding team members

The founding team members included:

• Thomas B. Bridges (Chairman and CEO)
• Dr. Herbert Allen
• Shane J. Schilroth (COO)

Initial capital/funding

Information regarding the company's initial capital and funding is not readily available.

Cingulate Inc.'s Evolution Milestones

Cingulate Inc.'s Transformative Moments

• Focus on ADHD Treatment: The company's strategic focus on addressing the unmet needs in ADHD treatment has been a key driver of its development. This focus has allowed it to target a significant market with innovative solutions.
• Innovative Drug Delivery Technology: Cingulate Inc.'s development of an innovative drug delivery technology has the potential to differentiate its products from existing treatments. This technology aims to provide improved efficacy and safety profiles.
• Clinical Trial Progress: Advancing its lead drug candidates through clinical trials has been critical in demonstrating their potential value. Positive results from these trials have boosted investor confidence and propelled the company forward.
• Financial Milestones: Successfully completing an IPO has provided Cingulate Inc. with the necessary capital to fund its research and development activities. This financial milestone has enabled the company to progress its pipeline and pursue its strategic goals.

To gain more insights into the investors and motivations behind supporting Cingulate Inc., you might find this resource helpful: Exploring Cingulate Inc. (CING) Investor Profile: Who’s Buying and Why?

Cingulate Inc. (CING) Ownership Structure

Understanding the ownership structure of Cingulate Inc. (CING) provides insights into who controls the company and how its governance is structured, influencing its strategic decisions and overall direction.

Cingulate Inc.'s Current Status

Cingulate Inc. is a public company, trading on the NASDAQ under the ticker symbol 'CING.' This means that a portion of the company is owned by public investors through the stock market, while significant shares may still be held by institutional investors, private equity firms, or company insiders.

Cingulate Inc.'s Ownership Breakdown

The ownership of Cingulate Inc. is distributed among various types of shareholders, each holding a certain percentage of the company's stock. As of the fiscal year 2024, the ownership breakdown is as follows:

Cingulate Inc.'s Leadership

The leadership team is crucial for guiding Cingulate Inc.'s strategic direction and operational execution. Key members of the leadership team as of April 2025 include:

• Chairman and CEO: [Name of CEO]
• Chief Financial Officer (CFO): [Name of CFO]
• Chief Medical Officer (CMO): [Name of CMO]
• Board of Directors: A group of individuals with diverse expertise overseeing corporate governance.

For more insights into the company's guiding principles, you can read about the Mission Statement, Vision, & Core Values of Cingulate Inc. (CING).

Cingulate Inc. (CING) Mission and Values

Cingulate Inc. focuses on improving the lives of patients with attention deficit hyperactivity disorder (ADHD) and seeks to develop and commercialize new and innovative therapies to improve the lives of patients.

Cingulate Inc.'s Core Purpose

Official mission statement

Cingulate's official mission statement is: 'To develop and commercialize new and innovative therapies to improve the lives of patients.'

Vision statement

While a specific vision statement isn't explicitly available, insights into Cingulate's aspirations can be gathered:

• Cingulate aims to transform the treatment paradigm for ADHD by providing personalized solutions that address unmet clinical needs.
• They focus on developing and commercializing innovative therapies that improve the lives of patients.
• Cingulate strives to be a leader in the field of ADHD therapeutics, driving advancements in treatment options and patient care.

Company slogan/tagline

There is no specific slogan or tagline available.

For more in-depth information, see: Mission Statement, Vision, & Core Values of Cingulate Inc. (CING).

Cingulate Inc. (CING) How It Works

Cingulate Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD). They aim to improve the lives of patients by providing innovative treatments that address unmet needs in the ADHD market.

Cingulate's Product/Service Portfolio

Cingulate's Operational Framework

Cingulate operates through a focused approach to research, development, and potential commercialization of its product candidates. Their operational framework includes:

• Research and Development: Concentrating on creating and testing new formulations of existing ADHD medications to improve their effectiveness and patient compliance.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their product candidates, CTX-1301 and CTX-1302.
• Regulatory Approval: Seeking regulatory approval from the U.S. Food and Drug Administration (FDA) to market their products.
• Manufacturing and Supply Chain: Establishing manufacturing processes and a reliable supply chain to ensure product availability if and when their products receive FDA approval.
• Commercialization: Preparing for the commercial launch of their products, which may involve building a sales and marketing team or partnering with other pharmaceutical companies.

To gain more insight into the guiding principles behind Cingulate's work, explore their Mission Statement, Vision, & Core Values of Cingulate Inc. (CING).

Cingulate's Strategic Advantages

Cingulate's strategic advantages in the biopharmaceutical industry stem from several key factors:

• Innovative Formulations: Novel timed release Multi-Particulate (MP) formulations of common ADHD medications could offer improved efficacy and patient compliance.
• Targeted Approach: Focusing specifically on ADHD allows Cingulate to concentrate its resources and expertise.
• Experienced Team: A management team with experience in drug development and commercialization helps guide the company's strategy and execution.
• Intellectual Property: Patents and other intellectual property protections for their formulations can provide a competitive edge.

Cingulate Inc. (CING) How It Makes Money

Cingulate Inc. is a biopharmaceutical company that primarily focuses on developing and commercializing treatments for attention deficit hyperactivity disorder (ADHD). The company's revenue model is centered on the successful development, regulatory approval, and subsequent sales of its pharmaceutical products.

Revenue Breakdown

As a clinical-stage pharmaceutical company, Cingulate Inc.'s revenue generation is contingent upon the successful development and commercialization of its product candidates. Currently, the company does not have any products approved for sale, and therefore, it is not generating revenue from product sales. However, potential future revenue streams can be estimated based on the progress of their pipeline drugs and market conditions.

Business Economics

The economic model of Cingulate Inc. is heavily influenced by the high-risk, high-reward nature of the pharmaceutical industry. Key aspects of its business economics include:

• R&D Expenses: A significant portion of the company’s expenditure is allocated to research and development.
• Clinical Trial Costs: Clinical trials represent a major expense, with costs escalating as drug candidates progress through Phase 1, 2, and 3 trials.
• Regulatory Approval: Securing regulatory approval from bodies such as the FDA is crucial but can be a lengthy and costly process.
• Market Exclusivity: Patents and market exclusivity periods are vital for recouping investment and generating profit.
• Partnerships: Strategic alliances and partnerships can provide financial support and expertise.

Financial Performance

Given that Cingulate Inc. is in the clinical stage, traditional financial metrics may not fully reflect its potential. However, key indicators of its financial health include:

• Cash Runway: The amount of cash on hand and the projected burn rate determine how long the company can sustain operations without additional funding.
• Operating Expenses: Monitoring operating expenses, including R&D and administrative costs, is crucial for assessing financial discipline.
• Net Loss: As a development-stage company, Cingulate Inc. is likely to incur net losses until its products are commercialized.
• Financing Activities: The company’s ability to raise capital through equity or debt offerings is vital for funding its operations.

To gain more insights into the financial health of Cingulate Inc. (CING), you can explore this resource: Breaking Down Cingulate Inc. (CING) Financial Health: Key Insights for Investors

Cingulate Inc. (CING) Market Position & Future Outlook

As of April 2025, Cingulate Inc. is navigating a competitive pharmaceutical landscape with a focus on attention deficit hyperactivity disorder (ADHD) treatments. Their future success hinges on clinical trial outcomes, regulatory approvals, and successful commercialization of their product candidates. More information about the company’s goals can be found here: Mission Statement, Vision, & Core Values of Cingulate Inc. (CING).

Competitive Landscape

Opportunities & Challenges

Industry Position

• Cingulate Inc. is a development-stage pharmaceutical company, so its current industry position is largely based on the potential of its pipeline.
• The company aims to differentiate itself through innovative drug formulations designed to improve the treatment experience for patients with ADHD.
• Success depends on navigating the regulatory landscape, securing funding, and effectively competing with established players in the ADHD market.